# Massachusetts Alzheimer's Disease Research Center

> **NIH NIH P30** · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $48,680

## Abstract

OVERVIEW: Massachusetts Alzheimer’s Disease Research Center (MADRC)
The MADRC is an interdisciplinary Center at Massachusetts General Hospital, Harvard Medical School, with
two major strategic goals: 1) to understand the underpinnings of heterogeneity of Alzheimer’s disease and
Alzheimer’s Disease Related Disorders, and 2) to develop techniques, strategies, and technologies to
accelerate a cure. To approach these goals, we propose 7 Cores (Administrative, Clinical, Biomarker,
Imaging, Neuropathology, Data, and Outreach). We will use advanced Imaging, Biomarker, and analytic
approaches to study our Research Cohort, which we view as a state of the art clinical phenotyping laboratory.
Autopsy follow up for validation of biomarkers and imaging, and therapeutic targets, is essential. We plan to
study a diverse population, both in the sense of various pathophysiologies, and also with varying racial and
ethnic backgrounds, and rely on a vigorous ORE core both to fulfill our own recruitment needs and to support
clinical trials and other affiliated programs.
We have refocused our Center’s activities by remodeling the Research Cohort to include subjects who are
cognitively normal, have mild cognitive impairment, or dementia, targeting diverse causes of dementia
including Alzheimer’s disease and related disorders (Frontotemporal dementia, Lewy Body Disease, and
vascular lesions). We postulate that heterogeneity of progression, even among individuals with the same
“disease”, reflects underlying differences that can be uncovered, and that doing so will enhance clinical trial
design by parsing variability from the very large, long cohort trials now in common use.
Each Core is challenged to develop tools to help accelerate a cure – from intermediate imaging/biomarker
targets that may help with diagnosis (a patient’s state) or prognosis (a patient’s fate), to performing autopsies
to validate those targets. We will develop markers of inflammation and neurodegeneration, believing that
innate immunity and resilience play a role in addition to tangles and plaques. Development of statistical and
data methods are critical for anlaysis. These tools will allow us to test hypotheses about faster or slower rates
of progression in a deeply phenotyped cohort.
A final goal, central to our mission, is to build the future by training the next generation of scientists, which we
propose to do under the framework of the Research Education Component. Together, we hope to make a
difference in these devastating diseases.

## Key facts

- **NIH application ID:** 9980590
- **Project number:** 3P30AG062421-01S2
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** BRADLEY T. HYMAN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $48,680
- **Award type:** 3
- **Project period:** 2019-04-15 → 2020-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9980590

## Citation

> US National Institutes of Health, RePORTER application 9980590, Massachusetts Alzheimer's Disease Research Center (3P30AG062421-01S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9980590. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*